| 1. |
|
|
| 2. |
|
|
| 3. |
- Lundholm, Lukas, et al.
(författare)
-
VERDICT MRI for radiation treatment response assessment in neuroendocrine tumors.
- 2022
-
Ingår i: NMR in biomedicine. - : Wiley. - 1099-1492 .- 0952-3480. ; 35:6
-
Tidskriftsartikel (refereegranskat)abstract
- Non-invasive methods to study changes in the tumor microstructure would enable early assessment of treatment response and thus facilitate personalized treatment. The aim of this study was to evaluate the diffusion MRI model Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumors (VERDICT) for early response assessment to external radiation treatment and to compare the results to those of more studied sets of parameters derived from diffusion-weighted MRI data. Mice xenografted with human small intestine tumors were treated with external radiation treatment, and diffusion MRI experiments were performed on the day before and up to two weeks after treatment. The diffusion models VERDICT, ADC, IVIM, and DKI were fitted to MRI data, and the treatment response of each tumor was calculated based on pre-treatment tumor growth and post-treatment tumor volume regression. Linear regression and correlation analysis were used to evaluate each model and their respective parameters for explaining the treatment response. VERDICT analysis showed significant changes from day -1 to day 3 for the intracellular and extracellular volume fraction, as well as the cell radius index (P < 0.05; Wilcoxon signed-rank test). The strongest correlation between the diffusion model parameters and the tumor treatment response was seen for the ADC, kurtosis-corrected diffusion coefficient, and intracellular volume fraction on day 3 (τ = 0.47, 0.52, and -0.49 respectively, P < 0.05; Kendall rank correlation coefficient). Of all tested models, VERDICT held the strongest explanatory value for the tumor treatment response on day 3 (R2 = 0.75, P < 0.01; linear regression). In conclusion, VERDICT holds potential for early assessment of external radiation treatment and may provide further insight into the underlying biological effects of radiation on tumor tissue. In addition, the results suggested that the time window for assessment of treatment response using dMRI may be narrow.
|
|
| 4. |
- Mirzaei, Nushin, et al.
(författare)
-
Sentinel lymph node localization and staging with a low-dose of superparamagnetic iron oxide (SPIO) enhanced MRI and magnetometer in patients with cutaneous melanoma of the extremity - The MAGMEN feasibility study
- 2022
-
Ingår i: European Journal of Surgical Oncology. - : Elsevier BV. - 0748-7983. ; 48:2, s. 326-332
-
Tidskriftsartikel (refereegranskat)abstract
- Background: In patients with melanoma, sentinel lymph node (SLN) status is pivotal for treatment decisions. Current routine for SLN detection combines Technetium99m (Tc99) lymphoscintigraphy and blue dye (BD). The primary aim of this study was to examine the feasibility of using a low dose of superparamagnetic iron oxide (SPIO) injected intracutaneously to detect and identify the SLN, and the secondary aim was to investigate if a low dose of SPIO would enable a preoperative MRI-evaluation of SLN status. Methods: Patients with melanoma of the extremities were eligible. Before surgery, a baseline MRI of the nodal basin was followed by an injection of a low dose (0.02–0.5 mL) of SPIO and then a second MRI (SPIO-MRI). Tc99 and BD was used in parallel and all nodes with a superparamagnetic and/or radioactive signal were harvested and analyzed. Results: Fifteen patients were included and the SLNB procedure was successful in all patients (27 SLNs removed). All superparamagnetic SLNs were visualized by MRI corresponding to the same nodes on scintigraphy. Micrometastatic deposits were identified in four SLNs taken from three patients, and SPIO-MRI correctly predicted two of the metastases. There was an association between MRI artefacts in the lymph node and the dose SPIO given. Discussion: It is feasible to detect SLN in patients with melanoma using a low dose of SPIO injected intracutaneously compared with the standard dual technique. A low dose of SPIO reduces the lymph node MRI artefacts, opening up for a non-invasive assessment of SLN status in patients with cancer. © 2022 The Authors
|
|
| 5. |
|
|
